GLR Partners’s Barinthus Biotherapeutics BRNS Stock Holding History

GLR Partners’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$821K	Hold	1,243,377	–	–	0.38%	51
2026 Q1	$707K	Buy	+1,243,377	New	+$819K	0.39%	51

Other funds holding BRNS

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GLR Partners's BRNS Position: Q2 2026 in Review

GLR Partners held its Barinthus Biotherapeutics (BRNS) position steady in Q2 2026 at 1,243,377 shares worth $821K. The position accounts for 0.38% of the portfolio, ranked #51.

GLR Partners first reported a position in BRNS in Q1 2026 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

GLR Partners held 1,243,377 shares of Barinthus Biotherapeutics worth $821K as of Q2 2026.
GLR Partners left its Barinthus Biotherapeutics share count unchanged in Q2 2026.
Barinthus Biotherapeutics made up 0.38% of GLR Partners's portfolio in Q2 2026, its #51 holding.
GLR Partners first reported a position in Barinthus Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on GLR Partners's 13F filing for Q2 2026, filed 27 Jul 2026.